Neutralising Antibodies and Myxovirus Resistance Protein A as a Marker of Biological Response to Interferon β
Authors:
J. Libertínová 1; E. Meluzínová 1; V. Maťoška 2; M. Zajac 3; E. Hynčicová 1; A. Tomek 1; M. Bojar 1
Authors‘ workplace:
Neurologická klinika 2. LF UK a FN v Motole, Praha
1; Laboratoř molekulární diagnostiky Nemocnice Na Homolce, Praha
2; Ústav lékařské mikrobiologie, 2. LF UK a FN v Motole, Praha
3
Published in:
Cesk Slov Neurol N 2014; 77/110(5): 638-641
Category:
Short Communication
Děkuji doc. MU Dr. Petrovi Marusičovi, Ph.D. za připomínky k článku. Podpořeno grantem IGA MZ ČR NT 12385- 5.
Overview
Interferon β is the first-line treatment for relapsing-remitting multiple sclerosis. Patients treated with interferon β may develop neutralizing antibodies that can reduce or abolish its efficacy. Interferon-inducible Myxovirus resistance protein A has been proven to be a sensitive marker of biological response to interferon β. Neutralizing antibodies and the levels of Myxovirus resistance protein A mRNA are sensitive measures of biological response to interferon β; their levels should be investigated in all interferon-treated patients.
Key words:
interferon b – multiple sclerosis – neutralizing antibodies – Myxovirus resistance protein A
The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.
The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.
Sources
1. Pachner A, Narayan K, Price N, Hurd M, Dail D. MxA gene expression analysis as an interferon ‑ b bioactivity measurement in patients with multiple sclerosis and the identification of antibody ‑ mediated decreased bioactivity. Mol Diagn 2003; 7(1): 17 – 25.
2. Deisenhammer F, Reindl M, Harvey J, Gasse T, Dilitz E,Berger T. Bioavailability of interferon ‑ b ‑ 1b in MS patients with and without neutralizing antibodies. Neurology 1999; 52(6): 1239 – 1243.
3. Bertolotto A, Gilli F, Sala A, Capobianco M, Malucchi S, Milano E et al. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. Neurology 2003; 60(4): 634 – 639.
4. Hesse D, Sørensen PS. Using measurements of neutralizing antibodies: the challenge of IFN‑beta therapy. Eur J Neurol 2007; 14(8): 850 – 859.
5. Hoffmann S, Cepok S, Grummel V, Lehmann‑Horn K, Hackermuller J, Stadler PF et al. HLA‑DRB1*0401 and HLA‑DRB1*0408 are strongly associated with the development of antibodies against interferon ‑ b therapy in multiple sclerosis. Am J Hum Genet 2008; 83(2): 219 – 227. doi: 10.1016/ j.ajhg.2008.07.006.
6. Polman CH, Bertolotto A, Deisenhammer F, Giovannoni G, Hartung HP, Hemmer B et al. Recommendations for clinical use of data on neutralizing antibodies to interferon‑beta therapy in multiple sclerosis. Lancet Neurol 2010; 9(7): 740 – 750. doi: 10.1016/ S1474 ‑ 4422(10)70103 ‑ 4.
7. Sorensen PS, Koch ‑ Henriksen N, Ross C, Clemmesen KM, Bendtzen K. Appearance and disappearance of neutralizing antibodies during interferon‑beta therapy. Neurology 2005; 65(1): 33 – 39.
8. Cantillon M, Antonijevic I. Clinical relevance of anti‑drug antibodies with interferon beta‑1b therapy in multiple sclerosis. Mult Scler 2007; 13 (Suppl 1): S21 – S27.
9. Sorensen PS, Koch ‑ Henriksen N, Bendtzen K. Are ex vivo neutralising antibodies against IFN ‑ b always detrimental to therapeutic efficacy in multiple sclerosis? Mult Scler 2007; 13(5): 616 – 621.
10. Sorensen PS, Koch ‑ Henriksen N, Flachs EM, Bendtzen K. Is the treatment effect of IFN‑beta restored after the disappearance of neutralizing antibodies? Mult Scler 2008; 14(6): 837 – 842. doi: 10.1177/ 1352458508088942.
11. Petersen B, Bendtzen K, Koch ‑ Henriksen N, Ravnborg M, Ross C, Sorensen PS. Persistence of neutralizing antibodies after discontinuation of IFN‑beta therapy in patients with relapsing ‑ remitting multiple sclerosis. Mult Scler 2006; 12(3): 247 – 252.
12. Sominanda A, Lundkvist M, Fogdell ‑ Hahn A, Hemmer B, Hartung HP, Hillert J et al. Inhibition of endogenous interferon beta by neutralizing antibodies against recombinant interferon ‑ b. Arch Neurol 2010; 67(9): 1095 – 1101. doi: 10.1001/ archneurol.2010.218.
13. Sørensen PS, Deisenhammer F, Duda P, Hohlfeld R, Myhr KM, Palace J et al. Guidelines on use of anti‑IFN‑beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN‑beta antibodies in multiple sclerosis. Eur J Neurol 2005; 12(11): 817 – 827.
14. Gilli F, Marnetto F, Caldano M, Valentino P, Granieri L, Di Sapio A et al. Anti‑interferon‑beta neutralising activity is not entirely mediated by antibodies. J Neuroimmunol 2007; 192(1 – 2): 198 – 205.
15. Pachner AR, Bertolotto A, Deisenhammer F. Measurement of MxA mRNA or protein as a biomarker of IFN‑beta bioactivity: detection of antibody ‑ mediated decreased bioactivity (ADB). Neurology 2003; 61 (Suppl 5): S24 – S26.
16. Hesse D, Sellebjerg F, Sorensen PS. Absence of MxA induction by interferon ‑ b in patients with MS reflects complete loss of bioactivity. Neurology 2009; 73(5): 372 – 377. doi: 10.1212/ WNL.0b013e3181b04c98.
17. Gilli F, Marnetto F, Caldano M, Sala A, Malucchi S,Di Sapio A et al. Biological responsiveness to first injections of interferon ‑ b in patients with multiple sclerosis. J Neuroimmunol 2005; 158(1 – 2): 195 – 203.
18. Libertínová J, Kumstýřová T, Meluzínová E, Bojar M,Maťoška V. mRNA MxA jako marker biologické účinnosti léčby interferonem ‑ b u pacientů s RS v ČR. Cesk Slov Neurol N 2009; 72/ 105 (Suppl 2): S120.
19. van der Voort LF, Kok A, Visser A, Oudejans CBM, Caldano M, Gilli F et al. Interferon‑beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice. Mult Scler 2009; 15(2): 212 – 218. doi: 10.1177/ 1352458508096877.
20. van der Voort LF, Visser A, Knol DL, Oudejans CB,Polman CH, Killestein J. Lack of interferon‑beta bioactivity is associated with the occurrence of relapses in multiple sclerosis. Eur J Neurol 2009; 16(9): 1049 – 1052. doi: 10.1111/ j.1468 ‑ 1331.2009.02649.x.
21. Bojar M, Zajac M, Meluzinová E, Houzvickova E, Libertinova J, Liskova P et al. Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti‑interferon‑beta antibody ‑ positive patients with multiple sclerosis. Mult Scler 2010; 16(12): 1529 – 1530. doi: 10.1177/ 1352458510382248.
22. Klinický standard pro diagnostiku a léčbu roztroušené sklerózy a neuromyelitis optica. Dostupné z URL: http:/ / www.imuno.neurologiefnhk.cz/ doc/ Dx_Tx_RSaNMO ‑ standard.pdf.
Labels
Paediatric neurology Neurosurgery NeurologyArticle was published in
Czech and Slovak Neurology and Neurosurgery
2014 Issue 5
Most read in this issue
- Czech Training Version of the Montreal Cognitive Assessment (MoCA‑ CZ1) for Early Identification of Alzheimer Disease
- Leukodystrophies – Clical and Radiological Findings
- Barriers of Nervous System under Physiological and Pathological Conditions
- Surgical Treatment of Supratentorial Cortico‑ subcortical Cavernous Malformation